Clinical trial
A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
NCT02460679 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 14, 2016
- Completion date
- February 23, 2018
- Enrollment
- 19 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.